Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

TLDR

Unique patient‑specific tumor antigens may dominate the antitumor immune response. The study proposes that vaccinating patients with their own tumor antigen repertoire—without needing to characterize each antigen—offers a superior, broadly applicable strategy to elicit protective immunity regardless of tumor tissue availability. The study demonstrates that dendritic cells transfected with tumor‑derived mRNA elicit potent CTL responses and protective immunity in mice, and that tumor mRNA from murine lines or primary human cells can be amplified without loss of function.

Abstract

Unique patient-specific tumor antigens may constitute the dominant antigens in the antitumor immune response. Hence, vaccination with the patient's own repertoire of tumor antigens may offer a superior strategy to elicit protective immunity. We have shown previously that dendritic cells transfected with mRNA isolated from tumor cells stimulate potent CTL responses and engender protective immunity in tumor-bearing mice. In the current study, we demonstrate that tumor mRNA, isolated from murine tumor cell lines or from primary human tumor cells microdissected from frozen tissue sections, can be amplified without loss of function. This study provides the foundations for an effective and broadly applicable treatment that does not require the characterization of the relevant antigenic profile in each patient and will not be limited by tumor tissue availability for antigen preparation.